Edwards Lifesciences introduced TAVR to the ... transcatheter aortic valve replacement procedures. Third quarter U.S. TAVI sales of $55 million were off […] 3D medical animation services have ...

Also known as TAVR, this is a means of replacing a faulty aortic heart valve without resorting to open-heart surgery. Previously, Edwards expected full-year sales to advance 8% to 10%. The ...

Edwards Lifesciences Corporation (NYSE ... Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) physicians and a follow-up survey of thirty doctors ...

citing a turnaround in its position in the market for transcatheter aortic valve replacement (TAVR). Analyst Rick Wise argued that Edwards Lifesciences (NYSE:EW) shares have mainly remained range ...

Edwards Lifesciences ... in heart valve therapies and critical care technologies, has recently faced challenges in its core Transcatheter Aortic Valve Replacement (TAVR) business while ...

California-based Edwards (NYSE:EW) its only sell-equivalent rating on Wall Street amid 14 buy-equivalent ratings. Citing an FDA dataset from the company's Partner 3 trial for its TAVR heart valve ...

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued ...